Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Collaboration expense, net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

CRISPR Therapeutics

CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its CRISPR/Cas9 platform is a gene editing technology that allows for precise, directed changes to genomic DNA. The firm offers a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan and Craig Mellow on October 31, 2013 and is headquartered in Zug, Switzerland.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its CRISPR/Cas9 platform is a gene editing technology that allows for precise, directed changes to genomic DNA. The firm offers a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan, and Craig Mellow on October 31, 2013 and is headquartered in Zug, Switzerland.

CRISPR Therapeutics AG (CRSP) reported earnings 30 days ago. What's next for the stock?

Why Is CRISPR Therapeutics AG (CRSP) Up 45.9% Since Last Earnings Report?

ZUG, Switzerland and CAMBRIDGE, Mass., June 08, 2022 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team are scheduled to participate in the Goldman Sachs 43rd Annual Global Healthcare Conference on Wednesday, June 15, 2022, at 9:20 a.m. Pacific Time (PT).

CRISPR Therapeutics to Present at the Goldman Sachs 43rd Annual Global Healthcare Conference

Comcast

Crocs

Gilead Sciences

Goldman Sachs

Skyworks Solutions

Identifying oversold stocks gives investors the opportunity to buy shares that they perhaps already liked, only at a discounted price. The post 7 Oversold Stocks to Buy Right Now appeared first on InvestorPlace.

7 Oversold Stocks to Buy Right Now

Vertex Pharmaceuticals

BOSTON & ZUG, Switzerland & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and CRISPR Therapeutics (NASDAQ: CRSP) today announced new late-breaking clinical data accepted for oral presentation at the 2022 European Hematology Association (EHA) Congress. Vertex also announced three abstracts accepted for poster presentation at EHA. Late-breaking abstract #LB2367 entitled “Efficacy and Safety of A Single Dose of CTX001 For Transfusion-Dependent Βeta-Thalassem

Vertex and CRISPR Therapeutics Announce Acceptance of Late-Breaking Abstract for CTX001™ at the 2022 Annual European Hematology Association (EHA) Congress

ZUG, Switzerland and CAMBRIDGE, Mass., May 31, 2022 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that it will host an Innovation Day focused on early research and development on Tuesday, June 21, 2022 at 2:00 PM ET.

CRISPR Therapeutics to Host Innovation Day on June 21, 2022

Enservco

Longeveron

Martin Midstream Partners

Summit Midstream Partners LP

Tema Electrification ETF

The same strategies for buying stocks during a bull market don't apply during a recession. Learn what you need to do going forward.

How to Buy Stocks in a Recession

ZUG, Switzerland and CAMBRIDGE, Mass., May 16, 2022 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced the appointment of Phuong Khanh (P.K.) Morrow, M.D., FACP, as Chief Medical Officer, effective May 23, 2022. Dr. Morrow brings more than a decade of leadership experience in global drug development and joins CRISPR Therapeutics to lead the Company's global clinical development and regulatory operations.

CRISPR Therapeutics Announces the Appointment of Phuong Khanh Morrow, M.D., FACP, as Chief Medical Officer

While CRISPR Therapeutics' (CRSP) lead candidate is still a couple of years away from commercialization, it is highly dependent on collaboration revenues to fund its ongoing pipeline.

CRISPR (CRSP) Focuses on Pipeline Amid Lack of Marketed Drugs

ARK Industrial Innovation ETF

ARK Space Exploration & Innovation ETF

Shopify

Block

ARK Invest funds led by Cathie Wood seek long-term capital growth and focus mainly on disruptive innovation. Here's a look a five related stocks to consider.

5 Cathie Wood Stocks to Buy Now

Moderna

These two companies have been southbound lately.

2 Stocks With 75% to 183% Upside, According to Wall Street

ZUG, Switzerland and CAMBRIDGE, Mass., May 12, 2022 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that an abstract providing safety and efficacy data from the ongoing CTX130™ clinical trial for patients with T-cell lymphoma has been accepted for oral presentation at the Annual European Hematology Association (EHA) 2022 Hybrid Congress, taking place June 9 – 12, 2022, at the Messe Wien Exhibition and Congress Center in Vienna, Austria, and online. This will be the first clinical data presented from the CTX130 program.

CRISPR Therapeutics Announces Oral Presentation of New Clinical Data on Anti-CD70 Allogeneic CAR-T Therapy CTX130™ for Patients with T-cell Lymphoma at the Annual European Hematology Association (EHA) 2022 Hybrid Congress

RBC Capital Markets says it remains on the sidelines given commercial uptake for CRISPR Therapeutics' (NASDAQ: CRSP) sickle cell disease (SCD)/beta-thalassemia (BT) capped by preconditioning and has little conviction in BCMA/CD70 data within weeks.  The analysts .

Why This Analyst Has 'Little Conviction' On CRISPR's Upcoming Trial Data

CRISPR Therapeutics (CRSP) reports wider-than-expected Q1 loss. Revenues miss estimates.

CRISPR Therapeutics (CRSP) Q1 Earnings & Sales Miss Estimates

CRISPR Therapeutics AG (CRSP) delivered earnings and revenue surprises of -21.47% and 83.42%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

CRISPR Therapeutics AG (CRSP) Reports Q1 Loss, Lags Revenue Estimates

- More than 75 patients dosed with CTX001™ across CLIMB-Thal-111 and CLIMB-SCD-121 to date; planned global regulatory submissions on track for late 2022-

CRISPR Therapeutics Provides Business Update and Reports First Quarter 2022 Financial Results

ZUG, Switzerland and CAMBRIDGE, Mass., May 04, 2022 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team are scheduled to participate in the 2022 Bank of America Healthcare Conference on Wednesday, May 11, 2022, at 4:40 p.m. PT.

CRISPR Therapeutics to Present at the 2022 Bank of America Healthcare Conference

Ginkgo Bioworks Holdings

Novocure

These stocks are losers now. But they could be huge winners over the next few years.

3 Beaten-Down Stocks That Could Deliver 5X Gains By 2030

CRISPR Therapeutics continues to make progress in all of its development platforms. The company continues to confirm the filing date for CTX001.

Crispr Therapeutics: Progress, Risk, And Reward

Teladoc

These Cathie Wood Stocks have their risks but offer a massive upside potential ahead The post 3 Cathie Wood Stocks to Count on in Q2 appeared first on InvestorPlace. More From InvestorPlace Stock Prodigy Who Found NIO at $2… Says Buy THIS It doesn't matter if you have $500 in savings or $5 million.

3 Cathie Wood Stocks to Count on in Q2

BioMarin Pharmaceutical

Intercept Pharma

Ionis Pharma

Mirati Therapeutics

Novartis

Sarepta Therapeutics

Big biopharma companies usually rely on M&A to get immediate access to a new class of drug or technology, fill in the gap in their pipeline and compensate for revenue loss from patent expiration of blockbuster products. The post 7 Potential Biotech Stocks Buyout Targets in 2022 appeared first on InvestorPlace.

7 Potential Biotech Stocks Buyout Targets in 2022

Editas Medicine

Intellia Therapeutics

They point to trouble for investors counting on a rebound.

3 Ominous Reasons to Avoid This Biotech Pioneer

This company's targeting a market with explosive growth.

Is Now the Time to Bet on This Game-Changing Stock?

The only thing standing in the way is the clinical trials process, which takes time and patience.

CRISPR Stocks Are Huge -- Here's Why They'll Get Even Bigger by 2030

Abbott Labs

Thermo Fisher Scientific

Thinking about digging into immunization stocks? Let's look more broadly, into life sciences stocks.

News for CRISPR Therapeutics Stock (CRSP)